Molecular structure of Bufalin, CAS Number: 465-21-4
Bufalin (CAS 465-21-4)
See product citations (5)
Alternate Names:
(3β,5β)-3,14-Dihydroxybufa-20,22-dienolide; 5β,20(22)-Bufadienolide-3β,14-diol
Application:
Bufalin is inducer of apoptosis in human HL-60 and U-937 cell lines
CAS Number:
465-21-4
Purity:
≥98%
Molecular Weight:
386.52
Molecular Formula:
C24H34O4
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Bufalin, is a cardiotonic steroid originally isolated from the Chinese toad venom. Experiments have shown Bufalin to have demonstrated apoptotic and cell differentiation inducing properties in U-937 (sc-2239) cells through activation of AP-1 via a mitogen-activated protein kinase cascade. In conjunction, research has shown Bufalin to be an inhibitor of Na+/K+-ATPase which causes downregulation of mRNA transcripts encoding several isoforms of 14-3-3 gene. 14-3-3 proteins are multifunctional regulatory proteins, and the reduction in the abundance of various isoforms has been shown to have profound effects on cell function. Other studies have noted an enhancement of retinoic acid-induced differentiation of HL-60 (sc-2209) cells in primary culture.
Bufalin (CAS 465-21-4) References
- Na+, K+-ATPase inhibitors down-regulate gene expression of the intracellular signaling protein 14-3-3 in rat lens. | McGowan, MH., et al. 1999. J Pharmacol Exp Ther. 289: 1559-63. PMID: 10336553
- Induction of apoptosis by bufalin in human tumor cells is associated with a change of intracellular concentration of Na+ ions. | Kawazoe, N., et al. 1999. J Biochem. 126: 278-86. PMID: 10423518
- Quantification of nine bufadienolides of Shexiang Tongxin Dropping Pills in rat plasma and tissues using UPLC-MS/MS and its application to healthy and ischemia-reperfusion rats pharmacokinetic studies. | Zhao, J., et al. 2024. J Pharm Biomed Anal. 238: 115852. PMID: 37952449
- Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway. | Zhang, H., et al. 2023. J Transl Med. 21: 900. PMID: 38082327
- ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. | Soumoy, L., et al. 2024. Cancer Cell Int. 24: 8. PMID: 38178183
- Anti-Trypanosomal Bufadienolides from the Oocytes of the Toad Rhinella alata (Anura, Bufonidae). | Rodriguez, C., et al. 2023. Molecules. 29: PMID: 38202779
- Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells. | Gao, Y., et al. 2024. J Liposome Res. 34: 489-506. PMID: 38269490
- UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway. | Zhang, H., et al. 2024. Acta Biochim Biophys Sin (Shanghai). 56: 199-209. PMID: 38298057
- Mechanism of bufalin inhibition of colon cancer liver metastasis by regulating M2-type polarization of Kupffer cells induced by highly metastatic colon cancer cells. | Tang, D., et al. 2024. Apoptosis. 29: 635-648. PMID: 38393643
- Multi-b-value DWI to evaluate the synergistic antiproliferation and anti-heterogeneity effects of bufalin plus sorafenib in an orthotopic HCC model. | Guo, R., et al. 2024. Eur Radiol Exp. 8: 43. PMID: 38467904
- Steroid receptor coactivator 1 promotes human hepatocellular carcinoma invasiveness through enhancing MMP-9. | Tong, Z., et al. 2024. J Cell Mol Med. 28: e18171. PMID: 38506084
- Influence of Different Ratios of DSPE-PEG2k on Ester Prodrug Self-Assembly Nanoparticles for Cell Migration and Proliferation Suppression. | Zhang, H., et al. 2024. Int J Nanomedicine. 19: 2807-2821. PMID: 38525014
- Comprehensive Analysis of Bufadienolide and Protein Profiles of Gland Secretions from Medicinal Bufo Species. | Fang, Y., et al. 2024. Toxins (Basel). 16: PMID: 38535825
- Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. | Watabe, M., et al. 1998. Oncogene. 16: 779-87. PMID: 9488042
- Enhancement by bufalin of retinoic acid-induced differentiation of acute promyelocytic leukemia cells in primary culture. | Yamada, K., et al. 1998. Leuk Res. 22: 589-95. PMID: 9680108
Inhibitor of:
ATP1AL1, ATP1B3, ATPase, Dok-2, Na+ CP type Iα, Na+/K+ ATPase β4, Na+/K+-ATPase α1, Na+/K+-ATPase β1, Na+/K+-ATPase β2, NKAIN1, NKAIN2, NKAIN3, POLR3GL, SLIRP, sodium/potassium-ATPase α1, sodium/potassium-ATPase α3, sodium/potassium-ATPase β1, and Stat3.Activator of:
FXYD6, FXYD7, Na+ CP type IIβ, Na+ CP type Vα, Na+/K+-ATPase α2, Na+/K+-ATPase α3, Na+/K+-ATPase α4, NKAIN4, Nop14, SLC24A1, sodium/potassium-ATPase α1, and sodium/potassium-ATPase α3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bufalin, 10 mg | sc-200136 | 10 mg | $97.00 | |||
Bufalin, 25 mg | sc-200136A | 25 mg | $200.00 | |||
Bufalin, 50 mg | sc-200136B | 50 mg | $334.00 | |||
Bufalin, 100 mg | sc-200136C | 100 mg | $533.00 |